![Characterization of KRas pathway inhibitors in 2D and 3D screening formats](https://www.reactionbiology.com/wp-content/uploads/2023/06/ReactionBiology_KRAS-2D3D_Poster_0.png)
![Characterization of KRas pathway inhibitors in 2D and 3D screening formats](https://www.reactionbiology.com/wp-content/uploads/2023/06/ReactionBiology_KRAS-2D3D_Poster_0.png)
![Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers. NPJ Precision Oncology, 2021](https://www.reactionbiology.com/wp-content/uploads/2023/07/Vincent-paper-thumbnail-1.png)
Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers. NPJ Precision Oncology, 2021
![Establishment of a methodological platform for the exploration of MCL1 inhibitors](https://www.reactionbiology.com/wp-content/uploads/2023/07/MCL1_Poster_thumbnail.png)
Establishment of a methodological platform for the exploration of MCL1 inhibitors
![A systems biology approach combining ProLiFiler™ and Cancer Data Miner for an enhanced preclinical characterization of the Wee1 inhibitor adavosertib](https://www.reactionbiology.com/wp-content/uploads/2023/07/ReactionBiology_ProLiFiler_Poster.png)
A systems biology approach combining ProLiFiler™ and Cancer Data Miner for an enhanced preclinical characterization of the Wee1 inhibitor adavosertib
![Cell-Based Oncology Assays Brochure](https://www.reactionbiology.com/wp-content/uploads/2023/07/Cell-based_Brochure_thumbnail.png)